CR Group LP

Search
⚲

CR Group LP ✚
CRD #	132967
SEC #	801-63545
CIK #	0001702352, 0001747755
AUM	2,207.6 M (2026-03-31)
Employees	21 (43% Investors, 0% Brokers)
Phone	713-209-7350
Address	1000 Main Street, Suite 2500 Houston, TX 77002-6340
Source	[IAPD] [EDGAR] [Website] [LinkedIn]

Total AUM ($B) Copy

Type	Form D Funds	Date	Sold	AUM
PE	CRG Partners V Cayman Parallel Fund C LP	[2023-03-30]	526.5 M	371.0 M
	Offered $2,000,000,000 · Filed 2023-09-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,473,487,000 · Duration One year or less · Commission $77,346 · Revenue Decline to Disclose
PE	CRG Partners V Cayman Parallel Fund LP	[2023-03-30]	526.5 M	77.4 M
	Offered $2,000,000,000 · Filed 2023-09-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,473,487,000 · Duration One year or less · Commission $77,346 · Revenue Decline to Disclose
PE	CRG Partners V Delaware Parallel Fund LP	[2023-03-30]	526.5 M	95.1 M
	Offered $2,000,000,000 · Filed 2023-09-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,473,487,000 · Duration One year or less · Revenue Decline to Disclose
PE	CRG Partners IV - Cayman Levered LP	[2019-03-29]		166.1 M
	Filed 2019-10-11 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE	CRG Partners IV LP	[2019-03-29]	229.8 M	165.2 M
	Filed 2019-10-11 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE	CRG Partners IV - Parallel Fund C Cayman LP	[2019-03-29]	600.0 M	338.3 M
	Filed 2019-10-11 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE	CRG Partners III Cayman LP	[2016-03-29]	89.0 M	61.9 M
	Filed 2016-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $399,000 · Revenue Decline to Disclose
PE	CRG Partners III LP	[2016-03-29]	41.5 M	26.5 M
	Filed 2016-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $124,500 · Revenue Decline to Disclose
PE	CRG Partners III - Parallel Fund A LP	[2016-03-29]	27.3 M	18.9 M
	Filed 2016-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $409,500 · Revenue Decline to Disclose
PE	CRG Partners III - Parallel Fund B Cayman LP	2016-03-29		55.0 M
PE	Capital Royalty Partners II - Parallel Fund B Cayman LP	2013-04-01		5.8 M
PE	Parallel Investment Opportunities Partners II LP	[2013-04-01]	64.9 M	7.1 M
	Filed 2014-11-03 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE	Capital Royalty Parallel I LP	2012-03-29		64.7 M
PE	Capital Royalty Partners Cayman LP	2012-03-29		12.4 M
PE	Capital Royalty Partners II Cayman LP	[2012-03-29]	7.3 M	0.0 M
	Filed 2012-08-21 (D/A) · Exemption 506, 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $114,375 · Revenue Decline to Disclose
PE	Capital Royalty Partners II LP	[2012-03-29]	92.2 M	1.9 M
	Filed 2012-08-21 (D/A) · Exemption 506, 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $1,020,937 · Revenue Decline to Disclose
PE	Capital Royalty Partners II - Parallel Fund A LP	[2012-03-29]	80.9 M	3.3 M
	Filed 2013-01-04 (D/A) · Exemption 506, 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $507,913 · Revenue Decline to Disclose
PE	Capital Royalty Partners LP	2012-03-29		88.9 M
PE	Loan Star Credit Opportunities Master Fund I	2012-03-29		43.2 M

AUM Breakdown	Accounts	AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals)	0	0.0
(b) Individuals (high net worth individuals)	0	0.0
(c) Banking or thrift institutions	0	0.0
(d) Investment companies	0	0.0
(e) Business development companies	0	0.0
(f) Pooled investment vehicles	10	2.2
(g) Pension and profit sharing plans	0	0.0
(h) Charitable organizations	0	0.0
(i) State or municipal government entities	0	0.0
(j) Other investment advisers	0	0.0
(k) Insurance companies	0	0.0
(l) Sovereign wealth funds and foreign official institutions	0	0.0
(m) Corporations or other businesses not listed above	0	0.0
(n) Other	0	0.0
Total	10	2.2
By Discretionary
Discretionary	10	2.2
Non-Discretionary	0	0.0
Total	10	2.2
By Non-United States Persons
Non-United States Persons		1.7
United States Persons		0.5
Total	10	2.2

Form D Directors	Role	# Filings	# Firms
Sabrina Foster	Director	43	16
Omar Wright	Director	88	13
Charles Tate	Executive Officer	16	2
Nathan Hukill	Executive Officer, Promoter	9	2
Andrei Dorenbaum	Executive Officer, Promoter	7	2
Luke Duster	Executive Officer, Promoter	6	2
Sebastian Arango	Promoter	3	1
Adam Whitehead	Promoter	3	1
Meredith Gamble	Promoter	3	1
Crg Partners V Cayman GP LP	Executive Officer	1	1
View All

EDGAR Form	CIK	2011 - 2026
3	[0001702352]
4	[0001702352]
SC 13D	[0001702352]
SC 13G	[0001702352]
D	[0001747755]

Form 13D/13G Filer	Form 13D/13G Subject	Filed
CR Group LP	T2 Biosystems Inc	[2024-04-19]
CR Group LP	T2 Biosystems Inc	[2023-07-13]
CR Group LP	Assertio Holdings Inc	[2020-05-28]
CR Group LP	Tearlab Corp	[2020-05-21]
CR Group LP	Avinger Inc	[2020-02-13]
CR Group LP	Viveve Medical Inc	[2020-02-13]
Capital Royalty LP	Strongbridge Biopharma PLC	[2018-12-28]
Capital Royalty LP	Valeritas Holdings Inc	[2017-04-07]

Firm Profile (Form ADV)
Discretionary AUM	$1.0B
Serves	Institutional
Fund Types	Private Equity

Form 3/4/5 Subject	2011 - 2026
CRG Partners III - Parallel Fund B Cayman LP
CRG Partners III Cayman Lev AIV I LP
CRG Partners III - Parallel Fund A LP
CRG Partners III LP
CRG Partners III Cayman Unlev AIV I LP
CR Group LP
T2 Biosystems Inc
Avinger Inc
Loan Security Holdings I LLC
Assertio Holdings Inc
View All

Insider Transaction (Form 3/4/5)	Date	Action	Shares	Price	Value ($)
T2 Biosystems Inc TTOO Common Stock	2024-05-09	Conversion	108,752
T2 Biosystems Inc TTOO Series A Preferred Stock · derivative	2024-05-09	Conversion	17,160.48	$0.00
T2 Biosystems Inc TTOO Series B Preferred Stock · derivative	2024-05-09	Conversion	10,875.25	$0.00
T2 Biosystems Inc TTOO Common Stock	2024-05-09	Conversion	1,716,048
T2 Biosystems Inc TTOO Common Stock	2024-05-03	Grant	403,608
T2 Biosystems Inc TTOO Common Stock	2024-05-03	Grant	1,565,445
T2 Biosystems Inc TTOO Common Stock	2024-05-03	Grant	129,629
T2 Biosystems Inc TTOO Common Stock	2024-05-03	Grant	648,139
T2 Biosystems Inc TTOO Common Stock	2024-05-03	Grant	2,001,514
T2 Biosystems Inc TTOO Common Stock	2024-04-12	Grant	424,716
T2 Biosystems Inc TTOO Series A Convertible Preferred Stock · derivative	2024-04-12	Grant	17,160.48	$0.00
T2 Biosystems Inc TTOO Common Stock	2024-04-12	Grant	1,647,315
T2 Biosystems Inc TTOO Common Stock	2024-04-12	Grant	682,036
T2 Biosystems Inc TTOO Common Stock	2024-04-12	Grant	390,142
T2 Biosystems Inc TTOO Common Stock	2024-04-12	Grant	136,409
T2 Biosystems Inc TTOO Series B Preferred Stock · derivative	2024-02-14	Conversion	33,594.71	$0.00
T2 Biosystems Inc TTOO Common Stock	2024-02-14	Conversion	335,947
T2 Biosystems Inc TTOO Series B Preferred Stock · derivative	2024-02-14	Conversion	48,827.30	$0.00
T2 Biosystems Inc TTOO Common Stock	2024-02-14	Conversion	488,273
T2 Biosystems Inc TTOO Common Stock	2023-09-28	Sell	2,858,980	$0.16	457,437
showing 20 of 98 most recent transactions

Comparable Firms	State	AUM
Hidden Harbor Capital Management LP ✚	FL	2,235.2 M
EIV Capital LLC ✚	TX	2,232.2 M
CCMP Capital Advisors LP ✚	NY	2,229.0 M
Two Sigma Ventures LP ✚	NY	2,226.1 M
Longrange Capital LP ✚	CT	2,219.6 M
Further Global Capital Management LP ✚	NY	2,215.6 M
Kosmos Management LLC ✚	WA	2,205.9 M
Pacific Lake Partners LLC ✚	MA	2,179.9 M
CAI Manager LP ✚	CA	2,177.7 M
Ascend Capital Partners Manager LP ✚	NY	2,176.3 M

Assets, Funds, Holdings